PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) CEO Provides Corporate Update

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has released a corporate update from CEO and director Ben Nikolaevsky. The update includes information about the company’s new state-of-the-art facility, located in Pemberton, British Columbia, about 20 minutes north of Whistler, which was built to European Union GMP standards. The update also provides an overview of the company’s plans to undertake the operations of toll processing and white labelling for LPs that lack the extraction expertise and expensive equipment to provide their own materials. In addition, Pure Extracts is developing its own privateof products under Pure Pulls brand; the line should be available for sale by late Q1 2021. The update also noted that the company is expanding its business to include mushroom extracts by working on functional mushroom extraction processes utilizing existing infrastructure. Pure Extracts management sees a significant opportunity to become a key extraction partner for the commercialization of functional mushroom products. Additionally, the company anticipates entering the psychedelic mushroom market.

To view the full press release, visit https://ibn.fm/3Im1s

About Pure Extracts Technologies Corp.

Pure Extracts was incorporated under the BCBCA and has its offices and operations in Pemberton, British Columbia. On Sept. 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. On Nov. 5, 2020, Pure Extracts began trading on the CSE under the symbol PULL (“PULL”). Pure Extracts is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC- and CBD-based extracted oils. Additionally, Pure Extracts is presently expanding its business to include functional mushrooms extraction by working on processes compatible with its existing infrastructure. Pure Extracts has a C02 extraction facility built to European Union GMP standards and intends to seek EU GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal. For more information about the company, please visit www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Closes Acquisition of Dura Medical

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that its wholly owned subsidiary HOPE…

1 week ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join H.C. Wainwright’s 27th Annual Global Investment Conference; CEO Fireside Chat Set for Sept. 8, 2025, 4:30 to 5 p.m. ET

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc. (“HOPE”), an interventional…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Showcases HOPE Therapeutics at Global Passion Project Event 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, presented two keynote talks at the Global…

2 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced its expanded access policy for NRX-100…

3 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended…

1 month ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression 

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced the U.S. Food and Drug Administration…

1 month ago